Milestone Pharmaceuticals picks up $17 mln

Canada-based Milestone Pharmaceuticals, a drug developer focused on cardiovascular diseases, has raised $17 million in Series B funding. Domain Associates led the round with participation from other investors that included Fonds de solidarité FTQ, Pappas Ventures, BDC Capital, GO Capital and iNovia Capital. In conjunction with the funding, Domain's Debra Liebert has been added to Milestone's board of directors.

North AmericaUSBriefs